Introduction {#acn3521-sec-0001}
============

Dementia with Lewy bodies (DLB) is the second most common dementia type following Alzheimer\'s disease, accounting for 4.2% of all dementia cases in the population.[1](#acn3521-bib-0001){ref-type="ref"} In our population‐based study of residents of Olmsted County, Minnesota, the incidence rate of DLB was estimated at 3.5 per 100,000 person‐years, which significantly increased with age.[2](#acn3521-bib-0002){ref-type="ref"} Ante‐mortem diagnostic accuracy of DLB is important for clinical management and disease‐specific pharmacologic trials. The utility of ^123^I‐2*β*‐carbomethoxy‐3*β*‐(4‐iodophenyl)‐N‐(3‐fluoropropyl) nortropane (^123^I‐FP‐CIT) single‐photon emission computed tomography (SPECT) in differentiating DLB from other dementia types has been evaluated.[3](#acn3521-bib-0003){ref-type="ref"} Decreased striatal dopamine transporter uptake of ^123^I‐FP‐CIT in DLB is thought to reflect nigrostriatal degeneration in Lewy body disease (LBD).[4](#acn3521-bib-0004){ref-type="ref"} In a multicenter phase III trial, abnormal ^123^I‐FP‐CIT SPECT findings had 77.7% sensitivity and 90.4% specificity for distinguishing probable DLB from other dementias.[3](#acn3521-bib-0003){ref-type="ref"} Given the high sensitivity and specificity of ^123^I‐FP‐CIT SPECT for the diagnosis of DLB when combined with other clinical features, the revised consensus criteria for the clinical diagnosis of DLB include ^123^I‐FP‐CIT SPECT as an indicative biomarker of DLB.[5](#acn3521-bib-0005){ref-type="ref"}

Limited studies have validated ^123^I‐FP‐CIT SPECT findings in DLB with neuropathologic confirmation.[6](#acn3521-bib-0006){ref-type="ref"}, [7](#acn3521-bib-0007){ref-type="ref"}, [8](#acn3521-bib-0008){ref-type="ref"} Decreased ^123^I‐FP‐CIT binding in putamen measured semiquantitatively showed 88% sensitivity and 100% specificity for predicting LBD pathology at autopsy.[6](#acn3521-bib-0006){ref-type="ref"} Abnormal ^123^I‐FP‐CIT SPECT on visual rating was associated with LBD pathology with 80% sensitivity and 92% specificity.[8](#acn3521-bib-0008){ref-type="ref"} Although high diagnostic accuracy of ^123^I‐FP‐CIT SPECT for DLB/LBD was seen in these studies, the findings were based only on European patients with dementia. Here, we assess the clinical, pathologic, and ^123^I‐FP‐CIT SPECT correlations in patients with dementia from one center in the United States.

Methods {#acn3521-sec-0002}
=======

Mayo Alzheimer\'s Disease Research Center (ADRC) participants who were diagnosed with a clinical dementia syndrome, underwent ^123^I‐FP‐CIT SPECT imaging (performed as part of an ongoing ADRC imaging biomarker study in neurodegenerative conditions), and had neuropathologic evaluation at autopsy were included in the study. These patients had been followed longitudinally until death or until they were no longer able to participate in the research program between August 2003 and May 2016. Consensus clinical diagnosis of a dementia type, including Alzheimer\'s disease dementia (ADem),[9](#acn3521-bib-0009){ref-type="ref"}, [10](#acn3521-bib-0010){ref-type="ref"} DLB,[5](#acn3521-bib-0005){ref-type="ref"}, [11](#acn3521-bib-0011){ref-type="ref"} primary progressive aphasia (PPA)/frontotemporal lobar degeneration (FTLD),[12](#acn3521-bib-0012){ref-type="ref"}, [13](#acn3521-bib-0013){ref-type="ref"} and corticobasal syndrome (CBS)[14](#acn3521-bib-0014){ref-type="ref"}, [15](#acn3521-bib-0015){ref-type="ref"} was made based on previously published criteria. Rapid eye movement (REM) sleep behavior disorder (RBD) was diagnosed based on clinical +/− polysomnographic features.[16](#acn3521-bib-0016){ref-type="ref"}

^123^I‐FP‐CIT SPECT (DaTscan, GE Healthcare, Chicago, IL) was performed 1--59 months prior to death according to previously published protocol.[17](#acn3521-bib-0017){ref-type="ref"} ^123^I‐FP‐CIT SPECT findings were interpreted by radiologists in a blinded manner, and were considered abnormal if there was unequivocally reduced uptake in one or both putamen based on visual inspection. A mean putamen to occipital ratio (mPOR) was calculated for each patient by placing regions of interest over the right and left putamen and ipsilateral occipital cortical tissue and averaging the right and left putamen to occipital ratios. The calculation of mPOR was blinded with respect to the visual rating results as well as the clinical and pathologic diagnoses.

Neuropathologic diagnosis was made using previously published neuropathologic criteria, including Braak stages,[18](#acn3521-bib-0018){ref-type="ref"}, [19](#acn3521-bib-0019){ref-type="ref"} Consortium to Establish a Registry for Alzheimer\'s Disease scores,[19](#acn3521-bib-0019){ref-type="ref"}, [20](#acn3521-bib-0020){ref-type="ref"} Thal A*β* phases,[19](#acn3521-bib-0019){ref-type="ref"}, [21](#acn3521-bib-0021){ref-type="ref"} LBD pathologic criteria,[11](#acn3521-bib-0011){ref-type="ref"} and FTLD classification[22](#acn3521-bib-0022){ref-type="ref"} by neuropathologists who were blinded to the ^123^I‐FP‐CIT SPECT findings.

Comparisons for semiquantitatively analyzed ^123^I‐FP‐CIT SPECT findings between pathologically confirmed LBD and non‐LBD cases were made using two‐sided Wilcoxon rank‐sum test due to non‐normal distribution of the variable with a *P* \< 0.05 being considered statistically significant. Statistical analysis was performed using JMP, version 10.0 (SAS Institute Inc, Cary, NC).

This study was approved by the Mayo IRB. Informed consent was obtained from the patients and/or their proxies.

Results {#acn3521-sec-0003}
=======

Eighteen patients met the inclusion criteria, of whom 12 had pathologic confirmation of LBD. The demographic, clinical, pathologic, and ^123^I‐FP‐CIT SPECT characteristics of these patients are summarized in the Table [1](#acn3521-tbl-0001){ref-type="table-wrap"}. The median age of onset of cognitive decline was 65.5 years (interquartile range \[IQR\] 59.5--71.0). These patients were longitudinally followed up for a median duration of 5 years (IQR 2--8). The patients with clinical diagnosis of AD predominantly presented with amnestic features, with impairment in other nonmemory domains. All DLB patients met criteria for probable DLB based on the third and fourth consensus criteria[5](#acn3521-bib-0005){ref-type="ref"}, [11](#acn3521-bib-0011){ref-type="ref"} (i.e., all patients had at least two of the core clinical features, but ^123^I‐FP‐CIT SPECT was *not* used for diagnosis). Patients who were diagnosed with DLB exhibited visuospatial and executive dysfunction in addition to memory impairment. Most of the DLB patients (11 of 12) had concurrent or subsequent development of parkinsonism and/or visual hallucinations. All patients with DLB were also diagnosed with polysomnography‐confirmed RBD (10 of 12) or probable RBD (pRBD, 2 of 12) based on a strong history of dream enactment behavior. In most cases, RBD preceded the onset of cognitive decline in DLB by a median duration of 11 years (IQR 3.8--16.3). One patient with clinical diagnosis of ADem (Case 1) had a history consistent with probable RBD, although polysomnography demonstrated equivocal findings. Another patient with ADem (Case 4) had polysomnographic evidence of REM sleep without atonia in the absence of any clinical history of dream enactment behavior. Both of these patients were taking antidepressants at the time of polysomnography. Two patients (Cases 3 and 16) showed clinical features of both DLB and ADem, and were diagnosed as mixed DLB and ADem. Asymmetric limb apraxia, rigidity, and myoclonus were seen in the patient with CBS in addition to cognitive symptoms. One patient (Case 6) presented with prominent language dysfunction characterized by dysnomia, impaired object knowledge, and variable performance on repetition and comprehension measures, and he was diagnosed with PPA.[13](#acn3521-bib-0013){ref-type="ref"}

###### 

Demographic, clinical, pathologic, and ^123^I‐FP‐CIT SPECT findings in 18 autopsied patients with dementia

  Case   Sex   AAO (years)   AAD (years)   Clinical course (years)   Clinical diagnosis   Pathologic diagnosis                       Braak tangle stage   Thal A*β* phase   Fourth cDLB likelihood   Age at ^123^I‐FP‐CIT SPECT (years)   ^123^I‐FP‐CIT SPECT to death (months)   ^123^I‐FP‐CIT SPECT visual inspection   mPOR
  ------ ----- ------------- ------------- ------------------------- -------------------- ------------------------------------------ -------------------- ----------------- ------------------------ ------------------------------------ --------------------------------------- --------------------------------------- ------
  1      M     60            70            10                        ADem/pRBD            AD                                         6                    5                 None                     70                                   1                                       Normal                                  3.6
  2      M     51            60            9                         CBS                  AD                                         6                    5                 None                     58                                   15                                      Normal                                  3.1
  3      M     52            57            5                         DLB/ADem/RBD         AD                                         5                    3                 None                     55                                   24                                      Normal                                  3.1
  4      M     62            73            11                        ADem/RSWA            AD/ALB                                     5                    3                 Low                      69                                   48                                      Normal                                  2.1
  5      M     56            62            6                         ADem                 AD[a](#acn3521-note-0004){ref-type="fn"}   4                    5                 None                     59                                   36                                      Abnormal                                3.2
  6      M     66            76            10                        PPA/bvFTD            FTLD‐TDP                                   2                    1                 None                     74                                   25                                      Normal                                  3.0
  7      M     76            86            12                        DLB/RBD              DLBD/PA                                    4                    3                 High                     86                                   6                                       Abnormal                                1.0
  8      M     70            75            5                         DLB/RBD              DLBD/PA                                    3                    2                 High                     74                                   17                                      Abnormal                                1.8
  9      M     58            61            3                         DLB/RBD              DLBD                                       2                    3                 High                     61                                   1                                       Abnormal                                1.4
  10     F     60            68            8                         DLB/pRBD             DLBD/AD                                    4                    4                 High                     64                                   45                                      Abnormal                                2.1
  11     F     70            78            8                         ADem                 DLBD/AD                                    6                    4                 Intermediate             75                                   27                                      Abnormal                                1.3
  12     M     65            80            15                        DLB/RBD              DLBD/PA                                    1                    3                 High                     75                                   59                                      Abnormal                                1.3
  13     M     70            81            11                        DLB/RBD              DLBD/PA                                    3                    1                 High                     77                                   48                                      Abnormal                                1.2
  14     M     65            75            10                        DLB/RBD              DLBD/PA                                    2                    2                 High                     72                                   43                                      Abnormal                                1.0
  15     M     77            87            10                        DLB/RBD              DLBD/AD                                    5                    4                 Intermediate             83                                   46                                      Abnormal                                1.2
  16     M     74            81            7                         DLB/ADem/RBD         DLBD/PA                                    2                    4                 High                     77                                   48                                      Abnormal                                2.0
  17     M     70            75            5                         DLB/pRBD             DLBD/AD                                    4                    4                 High                     72                                   32                                      Abnormal                                2.3
  18     M     77            85            8                         DLB/RBD              DLBD/PA                                    2                    3                 High                     81                                   42                                      Normal                                  2.1

All autopsied cases were Caucasian, except Case 18 who was an African American.

Fourth cDLB, fourth consortium\'s recommendation for likelihood of clinical dementia with Lewy bodies based on neuropathologic severity; AAD, age at death; AAO, age at onset; AD, Alzheimer\'s disease; ADem, Alzheimer\'s disease dementia; ALB, amygdala Lewy bodies; bvFTD, behavioral variant frontotemporal dementia; CBS, corticobasal syndrome; DLB, dementia with Lewy bodies; DLBD, diffuse Lewy body disease; F, female; FTLD‐TDP, frontotemporal lobar degeneration with TDP‐43 positive inclusions; ^123^I‐FP‐CIT, ^123^I‐2*β*‐carbomethoxy‐3*β*‐(4‐iodophenyl)‐N‐(3‐fluoropropyl) nortropane; M, male; mPOR, mean putamen to occipital ratio; PA, pathologic aging; PPA, primary progressive aphasia; pRBD, probable rapid eye movement sleep behavior disorder; RBD, polysomnography‐confirmed rapid eye movement sleep behavior disorder; SPECT, single‐photon emission computed tomography; TDP, TAR DNA‐binding protein 43.

Case 5 was found to have multiple metastatic melanoma nodules, predominantly found in frontal cortex and medial temporal lobe structures.
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The patients came to autopsy at a median age of 75.0 years (IQR 66.5--81.0) after 8.5 years (IQR 5.8--10.0) of clinical course. Neuropathologic diagnoses were mostly concordant with clinical diagnoses. Of 12 patients with neuropathologic features consistent with LBD, 11 were diagnosed with DLB. One patient (Case 11) diagnosed as ADem due to the absence of parkinsonism, fluctuating cognitive symptoms, visual hallucinations, and RBD was found to have mixed LBD and AD pathologies. Of six patients with non‐LBD pathology, only one patient (Case 3) carried a diagnosis of DLB, although he was clinically thought to have mixed dementia with DLB plus ADem features. The sensitivity and specificity of the clinical diagnosis for detecting underlying LBD pathology were 91.7% and 83.3%, respectively. Clinical diagnostic accuracy was 88.9%.

^123^I‐FP‐CIT SPECT was performed 34.0 months (IQR 16.5--46.5) prior to death. Representative ^123^I‐FP‐CIT SPECT images are shown in Figure [1](#acn3521-fig-0001){ref-type="fig"}. The median disease duration at the time of ^123^I‐FP‐CIT SPECT was 5.5 years (IQR 3.0--7.3). Eleven of 12 patients with LBD pathology, including mixed LBD and AD, had abnormal ^123^I‐FP‐CIT SPECT upon visual inspection (false negative Case 18). ^123^I‐FP‐CIT SPECT was considered normal in five of six patients with non‐LBD pathology (false positive Case 5). Reduced striatal uptake of ^123^I‐FP‐CIT on visual rating had sensitivity of 91.7% and specificity of 83.3% for detecting underlying LBD pathology. Diagnostic accuracy of ^123^I‐FP‐CIT SPECT using visual inspection was 88.9%. Semiquantitatively analyzed ^123^I‐FP‐CIT SPECT imaging demonstrated that mPOR in LBD cases was significantly reduced with a median mPOR of 1.4 (IQR 1.2--2.1), compared to a median mPOR of 3.1 (IQR 2.8--3.3) in non‐LBD cases (*P* = 0.002).

![^123^I‐FP‐CIT SPECT demonstrates reduced striatal uptake in LBD cases compared to non‐LBD cases. Representative images are shown. AD, Alzheimer\'s disease; ADem, Alzheimer\'s disease dementia; c, clinical diagnosis; CBS, corticobasal syndrome; DLB, dementia with Lewy bodies; FTLD, frontotemporal lobar degeneration; LBD, Lewy body disease; mPOR, mean putamen to occipital ratio; p, pathologic diagnosis; PPA, primary progressive aphasia](ACN3-5-376-g001){#acn3521-fig-0001}

Discussion {#acn3521-sec-0004}
==========

In this study, reduced striatal uptake of ^123^I‐FP‐CIT on visual rating was highly predictive of underlying LBD pathology in patients with dementia. Furthermore, semiquantitative analysis of ^123^I‐FP‐CIT SPECT revealed that a reduction in mPOR was strongly associated with LBD. These findings are consistent with the results of previous European studies (Table [2](#acn3521-tbl-0002){ref-type="table-wrap"}),[6](#acn3521-bib-0006){ref-type="ref"}, [7](#acn3521-bib-0007){ref-type="ref"}, [8](#acn3521-bib-0008){ref-type="ref"} and support the utility of ^123^I‐FP‐CIT SPECT in ante‐mortem clinical diagnosis of DLB.

###### 

Sensitivity, specificity, and accuracy of clinical diagnosis and ^123^I‐FP‐CIT SPECT for diagnosing dementia with Lewy bodies

                                                            Clinical diagnosis   ^123^I‐FP‐CIT SPECT                                                                            
  --------------------------------------------------------- -------------------- --------------------- ---- --- ---- ---- ---- ------------------ ---- --- ---- --- ----- ----- ----
  Walker et al.[6](#acn3521-bib-0006){ref-type="ref"}       6                    7                     5    2   75   42   55   Semiquantitative   7    0   12   1   88    100   95
  Visual rating                                             7                    2                     10   1   88   83   85                                                    
  Walker and Walker[7](#acn3521-bib-0007){ref-type="ref"}   8                    7                     6    2   80   46   61   Semiquantitative   10   1   12   0   100   92    96
  Thomas et al.[8](#acn3521-bib-0008){ref-type="ref"}       26                   7                     18   4   87   72   80   Visual rating      24   2   23   6   80    92    85
  Present study                                             11                   1                     5    1   92   83   89   Visual rating      11   1   5    1   92    83    89
  Combined                                                  51                   22                    34   9   85   61   73                      59   6   62   9   87    91    89

TP, true positive; FP, false positive; TN, true negative; FN, false negative; SN, sensitivity; SP, specificity.

John Wiley & Sons, Ltd

In earlier studies, clinical diagnosis of DLB showed decreased diagnostic accuracy in comparison to ^123^I‐FP‐CIT SPECT as the clinical diagnosis was made during the first clinical encounter by a single clinician without the input of an expert panel.[6](#acn3521-bib-0006){ref-type="ref"}, [7](#acn3521-bib-0007){ref-type="ref"} In the present study, clinical evaluation and ^123^I‐FP‐CIT SPECT overall yielded the same diagnostic accuracy in the group of 18 patients with dementia. However, ^123^I‐FP‐CIT SPECT was useful for predicting LBD pathology in a patient (Case 11) who lacked the core features of DLB, making the clinical diagnosis of DLB difficult. Similarly, ^123^I‐FP‐CIT SPECT predicted absence of LBD pathology in a patient (Case 3) whose diagnosis between pure clinical DLB and ADem was challenging as he met the clinical criteria of ADem, but also had RBD and characteristic cognitive impairment of DLB without other core DLB features. As such, ^123^I‐FP‐CIT SPECT may be particularly helpful when atypical clinical features or diagnostic ambiguities are present. However, ^123^I‐FP‐CIT SPECT alone is not sufficient to make a diagnosis of DLB, and should be used in conjunction with clinical features for the diagnosis of DLB.[5](#acn3521-bib-0005){ref-type="ref"}

In this series, the results from visual inspection of ^123^I‐FP‐CIT SPECT were mostly in agreement with mPOR. When discrepancy between visual rating and mPOR was present (Cases 5 and 18), mPOR appeared to be more consistent with the neuropathological findings. A potential limitation of visual rating in this study was the lack of assessment of interrater reliability as each ^123^I‐FP‐CIT SPECT was read by a single radiologist. However, evaluating the diagnostic utility of ^123^I‐FP‐CIT SPECT based on single radiologist interpretation is still meaningful as it mimics common clinical practice. Determining the superiority of semiquantitative analysis of ^123^I‐FP‐CIT SPECT over visual rating was not possible in this study as the lack of mPOR data in a sufficient number of neurologically normal controls made the determination of abnormal mPOR cut‐off difficult. A study comparing the qualitative and quantitative analyses of ^123^I‐FP‐CIT SPECT is underway.

Another potential limitation of the study was a relatively small sample size. However, autopsy validation of ^123^I‐FP‐CIT SPECT for predicting LBD strengthens the study findings. In addition, the results of the study were consistent with the findings of larger European studies, including \~10% of cases with LBD pathology with normal findings on ^123^I‐FP‐CIT SPECT.[6](#acn3521-bib-0006){ref-type="ref"}, [7](#acn3521-bib-0007){ref-type="ref"}, [8](#acn3521-bib-0008){ref-type="ref"} One would also predict neurodegenerative disorders associated with dementia plus striatonigral pathology such as progressive supranuclear palsy and corticobasal degeneration would have reduced uptake on ^123^I‐FP‐CIT SPECT, but since none of our patients had such pathologies, the generalizability to the full spectrum of patients with dementia cannot be addressed in this series. Another limitation was that the patients were evaluated by behavioral neurologists and their ^123^I‐FP‐CIT SPECT findings were interpreted by radiologists at a large tertiary referral center, which likely increased the clinical and imaging diagnostic accuracy. A larger prospective multicenter study assessing the diagnostic utility of ^123^I‐FP‐CIT SPECT in DLB with neuropathologic validation would increase the generalizability of the present findings.
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